MBX Biosciences
88 hedge funds and large institutions have $420M invested in MBX Biosciences in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 40 increasing their positions, 14 reducing their positions, and 12 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
186% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 14
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
60% more capital invested
Capital invested by funds: $263M → $420M (+$157M)
11% more funds holding
Funds holding: 79 → 88 (+9)
3.5% more ownership
Funds ownership: 106.72% → 110.22% (+3.5%)
48% less call options, than puts
Call options by funds: $848K | Put options by funds: $1.63M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$8.8M |
| 2 |
Millennium Management
New York
|
+$6.08M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$5.54M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$4.39M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$8.46M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.79M |
| 4 |
JP Morgan Chase
New York
|
-$1.97M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$1.29M |
MBX Hedge Fund Activity: Q2 2025 in Review
88 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in MBX Biosciences (MBX) for Q2 2025, worth a combined $420M — up 60% from $263M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new MBX positions and 12 closed out — a net gain of 9 holders — while 40 added to existing stakes and 14 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $8.8M. The largest seller was RA Capital Management, cutting an estimated $11.5M.
- 88 institutional investors held MBX Biosciences (MBX) as of Q2 2025, up from 79 in Q1 2025.
- Funds reported $420M of MBX Biosciences stock for Q2 2025, up 60% quarter-over-quarter.
- 21 funds opened new MBX Biosciences positions in Q2 2025 and 12 closed out, a net change of +9 holders.
- The largest MBX Biosciences buyer in Q2 2025 was Point72 Asset Management, an estimated $8.8M added.
- The largest MBX Biosciences seller in Q2 2025 was RA Capital Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2025.